Apimeds Pharmaceuticals US, Inc ( APUS ) IPO will take place March, 05 on the NYSE exchange under the ticker APUS.

The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on September 01, 2025.

See also: Benzinga IPO Calendar

About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. ( APUS ) is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom-based toxin, primary focus is to advance Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis ("OA") and, eventually, multiple sclerosis ("MS").

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.